Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
| العنوان: | Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial |
|---|---|
| المؤلفون: | Jean-Marc Phelip, Valérie Boige, Karine Le Malicot, Julien Taieb, Jean-Marc Gornet, Jaafar Bennouna, Olivier Bouché, Eric Francois, for Prodige investigators, Veronique Guerin-Meyer, Oana Cojocarasu, Marie-Christine Kaminsky, Joëlle Egreteau, Laetitia Dahan, Jean-Baptiste Bachet, François Ghiringhelli, Roger Faroux, Mohamed Gasmi, Thomas Aparicio, Christian Borel, Côme Lepage |
| المصدر: | British Journal of Cancer |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, Colorectal cancer, medicine.medical_treatment, Logistic regression, Article, law.invention, Free interval, Prognostic markers, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Humans, Aged, 030304 developmental biology, 0303 health sciences, Chemotherapy, business.industry, Induction chemotherapy, Induction Chemotherapy, medicine.disease, Clinical trial, 030220 oncology & carcinogenesis, Disease Progression, Female, Colorectal Neoplasms, business |
| الوصف: | Background Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying patients who may have a chemotherapy-free interval (CFI) after IC are two major challenges. Methods A logistic model was used to identify factors associated with early progression during IC and with short duration of the first CFI in 488 patients enrolled in the PRODIGE 9 trial. Independent factors were defined with a threshold 0.10. Results In multivariate analysis, baseline leukocytes >10 × 109/L (OR = 1.98 [1.02–3.8], p = 0.04), and stable or increasing CEA at 2 months (OR = 3.61 [1.68–7.75], p = 0.01) were independent factors associated with progression during IC. Male gender (OR = 1.725 [0.92–3.325], p = 0.09) and no tumour response at first evaluation (OR = 1.90 [0.96–3.76], p = 0.07) were significantly associated with a short CFI. The presence of BRAF V600E mutation was also associated with short CFI (OR = 4.59 [0.95; 22.3], p = 0.058). Conclusion High baseline leukocyte count and the lack of CEA decrease level at first evaluation were associated with early progression, and could be in favour of early chemotherapy intensification. Male gender, no tumour response at first evaluation and BRAF mutation are associated with a short CFI, and may be considered for maintenance chemotherapy after IC. Clinical trial number NCT00952029. |
| تدمد: | 1532-1827 0007-0920 |
| DOI: | 10.1038/s41416-020-0735-8 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e635185e7f3a285884a0b2b266498d https://doi.org/10.1038/s41416-020-0735-8 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....25e635185e7f3a285884a0b2b266498d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|---|
| DOI: | 10.1038/s41416-020-0735-8 |